Literature DB >> 8587375

Cyclosporine A stimulates endothelin release.

C Haug1, T Duell, R Voisard, A Lenich, H J Kolb, V Mickley, V Hombach, A Grünert.   

Abstract

Administration of cyclosporine A is often associated with the development of renal dysfunction and hypertension. Because recent data provide evidence that endothelin (ET) might be involved in mediating cyclosporine-associated cardiovascular and renal side effects, the present study aimed to investigate the influence of cyclosporine A on ET release from cultured smooth-muscle cells and whether ET plasma concentrations are elevated in cyclosporine-treated patients. Addition of cyclosporine A to the medium of cultured human smooth-muscle cells, isolated from atherosclerotic iliac arteries, induced a dose-dependent increase in ET release. ET plasma levels were significantly elevated in cyclosporine-treated patients after bone marrow transplantation, compared to control groups. These data suggest that enhanced ET release might be involved in mediating the cyclosporine-associated side effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587375

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

Authors:  P S Rangi; W J Partridge; E S Newlands; A D Waldman
Journal:  Neuroradiology       Date:  2005-07-05       Impact factor: 2.804

Review 2.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.